ClinConnect ClinConnect Logo
Search / Trial NCT00027326

Collection of Blood and Urine From Patients Undergoing Radiation Therapy

Launched by NATIONAL CANCER INSTITUTE (NCI) · Nov 30, 2001

Trial Information

Current as of September 24, 2025

Enrolling by invitation

Keywords

Blood Samples Radiation Urine Cancer Natural History

ClinConnect Summary

This is an observational study that will collect blood and urine from people who are receiving radiation therapy for cancer. The goal is to learn how radiation affects the body, by looking at changes in gene activity in white blood cells, any damage to red blood cells, and hormone levels in blood and urine. It’s a exploratory, pilot project planned to enroll about 1,000 participants at a few major centers (including the NIH Clinical Center, Johns Hopkins, and the University of Pennsylvania). Researchers will take samples when you enter the study, at the end of your radiation treatment, and about 1 month afterward. At this time, no results are available from the study.

Who can participate and what to expect: Adults 18 years and older who are about to start or are currently receiving radiation therapy may be eligible, as long as they are also enrolled in a NIH radiation-related protocol and can give informed consent. Blood and urine samples are usually collected during routine care, and any extra needle sticks are kept to a minimum. This is a purely observational study—no new treatments are given as part of the study. The collected samples and related health information may be stored for research and shared with other researchers in a controlled way to help understand radiation effects better. If you’re interested, talk with the study team to see if you might be eligible.

Gender

ALL

Eligibility criteria

  • * INCLUSION CRITERIA:
  • 1. Patients must be co-enrolled in a NIH CC protocol in which radiation will be administered.
  • 2. Patients must a candidate for, or currently receiving radiotherapy.
  • 3. Age greater than or equal to 18 years.
  • 4. Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.
  • EXCLUSION CRITERIA:
  • 1. Patients who have unobtainable data regarding previous radiation therapy.

About National Cancer Institute (Nci)

The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.

Locations

Bethesda, Maryland, United States

Bethesda, Maryland, United States

Patients applied

0 patients applied

Trial Officials

Kevin A Camphausen, M.D.

Principal Investigator

National Cancer Institute (NCI)

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials